Cargando…
Phenotyping COPD exacerbations using imaging and blood-based biomarkers
RATIONALE: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are caused by a variety of different etiologic agents. Our aim was to phenotype COPD exacerbations using imaging (chest X-ray [CXR] and computed tomography [CT]) and to determine the possible role of the blood tests (C-...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764289/ https://www.ncbi.nlm.nih.gov/pubmed/29386890 http://dx.doi.org/10.2147/COPD.S152484 |
_version_ | 1783292032731578368 |
---|---|
author | Alotaibi, Nawaf M Chen, Virginia Hollander, Zsuzsanna Hague, Cameron J Murphy, Darra T Leipsic, Jonathon A DeMarco, Mari L FitzGerald, J Mark McManus, Bruce M Ng, Raymond T Sin, Don D |
author_facet | Alotaibi, Nawaf M Chen, Virginia Hollander, Zsuzsanna Hague, Cameron J Murphy, Darra T Leipsic, Jonathon A DeMarco, Mari L FitzGerald, J Mark McManus, Bruce M Ng, Raymond T Sin, Don D |
author_sort | Alotaibi, Nawaf M |
collection | PubMed |
description | RATIONALE: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are caused by a variety of different etiologic agents. Our aim was to phenotype COPD exacerbations using imaging (chest X-ray [CXR] and computed tomography [CT]) and to determine the possible role of the blood tests (C-reactive protein [CRP], the N-terminal prohormone brain natriuretic peptide [NT-proBNP]) as diagnostic biomarkers. MATERIALS AND METHODS: Subjects who were hospitalized with a primary diagnosis of AECOPD and who had had CXRs, CT scans, and blood collection for CRP and NT-proBNP were assessed in this study. Radiologist blinded to the clinical and laboratory characteristics of the subjects interpreted their CXRs and CT images. ANOVA and Spearman’s correlation were performed to test for associations between these imaging parameters and the blood-based biomarkers NT-proBNP and CRP; logistic regression models were used to assess the performance of these biomarkers in predicting the radiological parameters. RESULTS: A total of 309 subjects were examined for this study. Subjects had a mean age of 65.6±11.1 years, 66.7% of them were males, and 62.4% were current smokers, with a mean FEV(1) 54.4%±21.5% of predicted. Blood NT-proBNP concentrations were associated with cardiac enlargement (area under the curve [AUC] =0.72, P<0.001), pulmonary edema (AUC =0.63, P=0.009), and pleural effusion on CXR (AUC =0.64, P=0.01); whereas on CT images, NT-proBNP concentrations were associated with pleural effusion (AUC =0.71, P=0.002). Serum CRP concentrations, on the other hand, were associated with consolidation on CT images (AUC =0.75, P<0.001), ground glass opacities (AUC =0.64, P=0.028), and pleural effusion (AUC =0.72, P<0.001) on CT images. A serum CRP sensitivity-oriented cutoff point of 11.5 mg/L was selected for the presence of consolidation on CT images in subjects admitted as cases of AECOPD, which has a sensitivity of 91% and a specificity of 53% (P<0.001). CONCLUSION: Elevated CRP may indicate the presence of pneumonia, while elevated NT-proBNP may indicate cardiac dysfunction. These readily available blood-based biomarkers may provide more accurate phenotyping of AECOPD and enable the discovery of more precise therapies. |
format | Online Article Text |
id | pubmed-5764289 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-57642892018-01-31 Phenotyping COPD exacerbations using imaging and blood-based biomarkers Alotaibi, Nawaf M Chen, Virginia Hollander, Zsuzsanna Hague, Cameron J Murphy, Darra T Leipsic, Jonathon A DeMarco, Mari L FitzGerald, J Mark McManus, Bruce M Ng, Raymond T Sin, Don D Int J Chron Obstruct Pulmon Dis Original Research RATIONALE: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are caused by a variety of different etiologic agents. Our aim was to phenotype COPD exacerbations using imaging (chest X-ray [CXR] and computed tomography [CT]) and to determine the possible role of the blood tests (C-reactive protein [CRP], the N-terminal prohormone brain natriuretic peptide [NT-proBNP]) as diagnostic biomarkers. MATERIALS AND METHODS: Subjects who were hospitalized with a primary diagnosis of AECOPD and who had had CXRs, CT scans, and blood collection for CRP and NT-proBNP were assessed in this study. Radiologist blinded to the clinical and laboratory characteristics of the subjects interpreted their CXRs and CT images. ANOVA and Spearman’s correlation were performed to test for associations between these imaging parameters and the blood-based biomarkers NT-proBNP and CRP; logistic regression models were used to assess the performance of these biomarkers in predicting the radiological parameters. RESULTS: A total of 309 subjects were examined for this study. Subjects had a mean age of 65.6±11.1 years, 66.7% of them were males, and 62.4% were current smokers, with a mean FEV(1) 54.4%±21.5% of predicted. Blood NT-proBNP concentrations were associated with cardiac enlargement (area under the curve [AUC] =0.72, P<0.001), pulmonary edema (AUC =0.63, P=0.009), and pleural effusion on CXR (AUC =0.64, P=0.01); whereas on CT images, NT-proBNP concentrations were associated with pleural effusion (AUC =0.71, P=0.002). Serum CRP concentrations, on the other hand, were associated with consolidation on CT images (AUC =0.75, P<0.001), ground glass opacities (AUC =0.64, P=0.028), and pleural effusion (AUC =0.72, P<0.001) on CT images. A serum CRP sensitivity-oriented cutoff point of 11.5 mg/L was selected for the presence of consolidation on CT images in subjects admitted as cases of AECOPD, which has a sensitivity of 91% and a specificity of 53% (P<0.001). CONCLUSION: Elevated CRP may indicate the presence of pneumonia, while elevated NT-proBNP may indicate cardiac dysfunction. These readily available blood-based biomarkers may provide more accurate phenotyping of AECOPD and enable the discovery of more precise therapies. Dove Medical Press 2018-01-08 /pmc/articles/PMC5764289/ /pubmed/29386890 http://dx.doi.org/10.2147/COPD.S152484 Text en © 2018 Alotaibi et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Alotaibi, Nawaf M Chen, Virginia Hollander, Zsuzsanna Hague, Cameron J Murphy, Darra T Leipsic, Jonathon A DeMarco, Mari L FitzGerald, J Mark McManus, Bruce M Ng, Raymond T Sin, Don D Phenotyping COPD exacerbations using imaging and blood-based biomarkers |
title | Phenotyping COPD exacerbations using imaging and blood-based biomarkers |
title_full | Phenotyping COPD exacerbations using imaging and blood-based biomarkers |
title_fullStr | Phenotyping COPD exacerbations using imaging and blood-based biomarkers |
title_full_unstemmed | Phenotyping COPD exacerbations using imaging and blood-based biomarkers |
title_short | Phenotyping COPD exacerbations using imaging and blood-based biomarkers |
title_sort | phenotyping copd exacerbations using imaging and blood-based biomarkers |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764289/ https://www.ncbi.nlm.nih.gov/pubmed/29386890 http://dx.doi.org/10.2147/COPD.S152484 |
work_keys_str_mv | AT alotaibinawafm phenotypingcopdexacerbationsusingimagingandbloodbasedbiomarkers AT chenvirginia phenotypingcopdexacerbationsusingimagingandbloodbasedbiomarkers AT hollanderzsuzsanna phenotypingcopdexacerbationsusingimagingandbloodbasedbiomarkers AT haguecameronj phenotypingcopdexacerbationsusingimagingandbloodbasedbiomarkers AT murphydarrat phenotypingcopdexacerbationsusingimagingandbloodbasedbiomarkers AT leipsicjonathona phenotypingcopdexacerbationsusingimagingandbloodbasedbiomarkers AT demarcomaril phenotypingcopdexacerbationsusingimagingandbloodbasedbiomarkers AT fitzgeraldjmark phenotypingcopdexacerbationsusingimagingandbloodbasedbiomarkers AT mcmanusbrucem phenotypingcopdexacerbationsusingimagingandbloodbasedbiomarkers AT ngraymondt phenotypingcopdexacerbationsusingimagingandbloodbasedbiomarkers AT sindond phenotypingcopdexacerbationsusingimagingandbloodbasedbiomarkers |